LILRB2 and non-small cell lung carcinoma: Additionally, EGFR–AKT/ERK1/2 signaling has been shown to upregulate ILT4 in NSCLC cells, facilitating M2-TAM recruitment and dampening T-cell immunity; blocking ILT4 synergizes with PD-L1 inhibitors in EGFR wild-type, but not EGFR-mutant tumors—underscoring an EGFR-driven immune evasion mechanism (126).